AU2003206862A1 - Hepatitis b vaccines - Google Patents

Hepatitis b vaccines

Info

Publication number
AU2003206862A1
AU2003206862A1 AU2003206862A AU2003206862A AU2003206862A1 AU 2003206862 A1 AU2003206862 A1 AU 2003206862A1 AU 2003206862 A AU2003206862 A AU 2003206862A AU 2003206862 A AU2003206862 A AU 2003206862A AU 2003206862 A1 AU2003206862 A1 AU 2003206862A1
Authority
AU
Australia
Prior art keywords
vaccines
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003206862A
Other versions
AU2003206862A8 (en
Inventor
Koen De-Heyder
Peter Schu
Michelle Serantoni
Jean Stephenne
Omer Van-Opstal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2003206862A8 publication Critical patent/AU2003206862A8/en
Publication of AU2003206862A1 publication Critical patent/AU2003206862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2003206862A 2002-02-07 2003-02-05 Hepatitis b vaccines Abandoned AU2003206862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202901.5 2002-02-07
GBGB0202901.5A GB0202901D0 (en) 2002-02-07 2002-02-07 Novel vaccine
PCT/EP2003/001214 WO2003066094A2 (en) 2002-02-07 2003-02-05 Hepatitis b vaccines

Publications (2)

Publication Number Publication Date
AU2003206862A8 AU2003206862A8 (en) 2003-09-02
AU2003206862A1 true AU2003206862A1 (en) 2003-09-02

Family

ID=9930627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206862A Abandoned AU2003206862A1 (en) 2002-02-07 2003-02-05 Hepatitis b vaccines

Country Status (3)

Country Link
AU (1) AU2003206862A1 (en)
GB (1) GB0202901D0 (en)
WO (1) WO2003066094A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060710A2 (en) * 2004-12-02 2006-06-08 Becton, Dickinson And Company Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN101500601A (en) 2005-04-18 2009-08-05 诺华疫苗和诊断公司 Expressing hepatitis B virus surface antigen for vaccine preparation
JP5135220B2 (en) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Multiple vaccinations including serogroup C meningococcus
EP1862176A1 (en) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
EP1862177A1 (en) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Method for producing a vaccine composition
JP2013522287A (en) 2010-03-18 2013-06-13 ノバルティス アーゲー Adjuvated vaccine for serogroup B meningococcus
JP6191082B2 (en) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Combination vaccine with lower dose of antigen and / or adjuvant
DE102011122891B4 (en) 2011-11-11 2014-12-24 Novartis Ag Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (en) 2011-11-11 2014-02-13 Novartis Ag Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN105007935A (en) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 Conjugates for protecting against diphtheria and/or tetanus
JP6475336B2 (en) * 2014-08-21 2019-02-27 チュン−アン ユニヴァーシティ インダストリー−アカデミー コーポレーション ファウンデーションＣｈｕｎｇ−Ａｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ rDNA NTS-based gene multiple insertion cassette set and GRAS grade recombinant yeast strain using the same
CN106222129A (en) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 A kind of cell culture medium improving antibody purity and cultural method
EP3634996A4 (en) * 2017-06-06 2021-03-03 InDevR, Inc. Simultaneous in vitro analysis of vaccine potency and toxin concentration
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515056A (en) * 1997-02-06 2002-05-21 メルク エンド カンパニー インコーポレーテッド Thimerosal-free preservative for vaccines
UA79735C2 (en) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Purification of hbv antigens for use in vaccines

Also Published As

Publication number Publication date
AU2003206862A8 (en) 2003-09-02
WO2003066094A2 (en) 2003-08-14
WO2003066094A3 (en) 2003-12-24
GB0202901D0 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
AU2003206862A1 (en) Hepatitis b vaccines
GB0226722D0 (en) Vaccine
AU2003301850A1 (en) Hiv vaccine
AU2003285320A1 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0328753D0 (en) Hepatitis B vaccines
AU2003237701A1 (en) Vaccines
PL376534A1 (en) Vaccine
AU2002236065A1 (en) Papillomavirus vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0229200D0 (en) Hepatitis B vaccines
AU2002351795A1 (en) Hepatitis x virus antigen
AU2002331950A1 (en) Vaccine
AUPS086102A0 (en) Vaccine iii
GB0226179D0 (en) Vaccine
GB0223355D0 (en) Vaccine
AU2002302785A1 (en) Vaccines
GB0200829D0 (en) Vaccines
GB0206462D0 (en) Vaccines
GB0217721D0 (en) Vaccines
GB0223045D0 (en) Vaccine
GB0221689D0 (en) Vaccine
GB0230170D0 (en) Vaccine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase